<DOC>
	<DOCNO>NCT00447759</DOCNO>
	<brief_summary>The Standard Care versus Celecoxib Outcome Trial ( SCOT ) large streamline safety study design compare cardiovascular safety celecoxib versus traditional non-selective Non Steroidal Anti-Inflammatory Drug ( NSAID ) therapy.Traditional NSAID 's associated significant morbidity mortality gastrointestinal toxicity . Cyclooxygenase 2 ( Cox-2 ) selective agent associate reduced upper gastrointestinal toxicity.Traditional NSAID 's Cox-2 inhibitor may also associate cardiovascular renal disorder . Data randomise observational study suggest celecoxib similar reduce cardiovascular toxicity compare traditional NSAID 's . However , overall safety balance strategy celecoxib therapy versus strategy NSAID therapy unknown . The European Medicines Evaluation Agency ( EMEA ) request study cardiovascular safety celecoxib carry within indicate population Europe . This study address issue compare cardiovascular safety celecoxib therapy traditional NSAID therapy set EU healthcare system . As May 2013 , 7300 patient randomise , accrue average 4.2 year follow end May 2014 .</brief_summary>
	<brief_title>The Standard Care Versus Celecoxib Outcome Trial</brief_title>
	<detailed_description>Aims The present proposal seek compare cardiovascular gastrointestinal safety effectiveness strategy initial randomisation treatment selective COX-2 inhibitor celecoxib 'usual-care ' current non-selective NSAID therapy ( without cyto-protection ulcer heal drug use either celecoxib 'usual-care ' limb ) . Trial Design This trial utilise Prospective Randomised Open Blinded End point ( PROBE ) design . Patients clinically diagnose osteoarthritis ( OA ) rheumatoid arthritis ( RA ) 60 year age free establish cardiovascular disease require chronic NSAID therapy identify set primary care . Patients randomise receive either celecoxib continue previous standard NSAID therapy . They follow average 4.2 year set local National Healthcare system . The study terminate 277 adjudicate cardiovascular event accrue . A summary show diagram .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<mesh_term>Diclofenac</mesh_term>
	<mesh_term>Ibuprofen</mesh_term>
	<mesh_term>Anti-Inflammatory Agents</mesh_term>
	<mesh_term>Anti-Inflammatory Agents , Non-Steroidal</mesh_term>
	<criteria>Subjects 60 year Male &amp; Female Chronic NSAIDs use 90 day 12 month period Subjects license indication chronic nonselective NSAID Celecoxib . Eligible treatment either Celecoxib alternative traditional nonselective NSAID . Subjects willing consent paper electronic medical record prescribe data access . Subjects willing contact interviewed trial investigator . Established cardiovascular disease include ischaemic heart disease , Myocardial Infarction , angina acute coronary syndrome , cerebrovascular disease cerebrovascular accident transient ischaemic attack , establish peripheral vascular disease moderate severe heart failure .</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Celecoxib</keyword>
	<keyword>Celebrex</keyword>
	<keyword>Ibuprofen</keyword>
	<keyword>Diclofenac</keyword>
	<keyword>NSAID</keyword>
	<keyword>Osteoarthritis</keyword>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>Arthritis</keyword>
	<keyword>Safety study</keyword>
	<keyword>Cardiovascular safety</keyword>
	<keyword>Clinical trial</keyword>
	<keyword>PROBE design</keyword>
	<keyword>University Dundee</keyword>
	<keyword>Medicines Monitoring Unit</keyword>
	<keyword>MEMO</keyword>
	<keyword>Professor Tom MacDonald</keyword>
</DOC>